Unicycive exchanges 43.6M Series A-2 preferred shares for 21,388 new preferred, amends warrants

Unicycive Therapeutics, Inc.

Exchanged 43,649,000 Series A-2 Preferred shares for 21,388.01 shares of new Series A-2 Prime Preferred.
Amended Tranche A, B, C warrants; reduced shares issuable, set exercise price at $1,000 per share.
New preferred series have conversion prices from $0.49 to $0.74 per share of common stock.
All prior Series A-1 through A-5 preferred eliminated via Certificates of Elimination.
Exchange treated as tax-free recapitalization under Sections 368(a)(1)(e) and/or 1036 of the Code.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Unicycive Therapeutics, Inc.: Filed Certificates of Elimination for five series of preferred stock and an Amended Certificate of Designation for new Series A Preferred Stock (effective 2024-03-14).

Change: charter amendment
Effective: 2024-03-14

Exact text from the filing

On March 13, 2024, the Company filed with the Delaware Secretary of State a Certificate of Elimination for each of the Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, Series A-4 Convertible Preferred Stock and Series A-5 Convertible Preferred Stock. Each Certificate of Elimination was filed with an effective date of 12:01 a.m. ET on March 14, 2024.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Effective: 2024-03-13

Exact text from the filing

On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred”

View on SEC.gov

245 governance changes filed in the last 30 days. Browse all governance changes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-022600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.